FGFR4 Recombinant Monoclonal Antibody

1. The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction. PMID: 29402970
2. These findings suggest that high levels of FGFR4 can increase glucose metabolism and lead to chemoresistance in breast cancer and reveal the mechanistic basis for targeting FGFR4 as a therapeutic opportunity for chemoresistant tumors. PMID: 29763898
3. Taken together, this study provides the first evidence that Blu9931 functions as a FGFR4-selective inhibitor in colorectal cancer (CRC) cells, and Blu9931 may be a new targeted drug. PMID: 29048661
4. Results show that FGFR4 promotes gastric cancer cell proliferation, migration and epithelial-to-mesenchymal transition. Its expression is negatively regulated by miR-491-5p through SNAIL protein. PMID: 29569792
5. Our findings indicate that the FGFR4-388Arg variant may play an important role in lung squamous cell carcinoma, which may be mediated by the overactivation of the MAPK pathway. PMID: 28583379
6. FGFR4 rs351855 could be a novel independent prognostic factor of BCR after radical prostatectomy in the Chinese population. PMID: 27640814
7. This meta-analysis demonstrates the FGFR rs351855 G>A polymorphism is associated with increased cancer risk. PMID: 28445975
8. Our results indicate that mRNA expression of FGFR4-related genes may be a biomarker to define the distinctive molecular phenotype of intrahepatic cholangiocarcinoma PMID: 28445152
9. The present study employed FGFR4 polymorphism to help identify treatments for high risk patients with stage III colon cancer. PMID: 27857023
10. Our data indicate that FGFR4 polymorphic isoforms mediate signaling that yields mitochondrial therapeutic targets of relevance to the actions of different somatostatin analogs. PMID: 27966451
11. In radiosensitive SW480 and DLD1 cells, enforced expression of FGFR4 stabilized RAD51 protein levels resulting in enhanced clearance of gamma-H2AX foci and increased cell survival in the mismatch repair (MMR)-proficient SW480 cells. PMID: 27650548
12. FGFR4/FGF19 autocrine signaling mediates the survival of a subset of basal-like breast cancer cells PMID: 27192118
13. Study shows that loss of FGFR4 expression led to a remarkable increase in sorafenib-induced ROS generation and apoptosis of hepatocellular carcinoma (HCC) cell lines, and demonstrates that hyperactivation of FGF19/FGFR4 signaling in HCC is one of the main mechanisms of sorafenib resistance. PMID: 28069043
14. This is the first study to elucidate FGF19/FGFR4 signaling in favor of hepatocellular carcinoma cells developing from fatty liver PMID: 27447573
15. High expression of FGFR4 is associated with hepatocellular carcinoma. PMID: 26498355
16. Findings show that FGF19 provides a cytoprotective role against ER stress by activating a FGFR4-GSK3beta-Nrf2 signaling cascade, suggesting targeting this signaling node as a candidate therapeutic regimen for hepatocellular carcinoma (HCC) management. PMID: 28951455
17. FGF23 augments pro-fibrotic signalling cascades in injury-primed renal fibroblasts via activation of FGFR4 PMID: 28919046
18. functional clathrin-mediated endocytosis is required for proper FGFR4 signaling PMID: 27615514
19. The frequency of the FGFR4 Arg388 (A) allele was significantly higher in hypertensive subjects (36%) than controls (24.3%). GA,AA, and GA+AA genotypes were significantly associated with risk of hypertension, even after adjusting for age, body mass index, and glucose. Gender stratification showed a significant association only in female subjects. Subjects with GA and AA genotypes showed higher diastolic blood pressure. PMID: 28650667
20. Enhanced myocardial expression of FGFR4 is associated with left ventricular hypertrophy in chronic kidney disease. PMID: 26681731
21. High FGFR4 expression was significantly associated with the depth of invasion, lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease in gastric cancer. PMID: 28056982
22. This study showed that Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. PMID: 26335532
23. Data suggest that knockdown of fibroblast growth factor receptor 4 (FGFR4) expression might prevent the growth of astric cancer (GC) in vivo. PMID: 26432329
24. FGFR4 is overexpressed in oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) in the absence of gene amplification, and may serve as a potential predictive marker for FGFR4-directed targeted therapy in OSCC and OPSCC. PMID: 26551585
25. Study shows that FGF19 can be secreted and promotes ovarian cancer progression such as proliferation and invasion by activating FGFR4. PMID: 26323668
26. The FGFR4 single-nucleotide polymorphism rs376618 had borderline significant differences in Patients With Primary Bile Acid Diarrhea. PMID: 26856750
27. Our study provides the first evidence of a role for FGFR4 in neuroblastoma PMID: 26840079
28. KL methylation is a characteristic of many breast cancer cases . However, the resulting or associated perturbation in FGFR4 expression, similar to FGF19, could be utilized as a biomarker for poor prognosis PMID: 26152288
29. The genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level PMID: 25860955
30. Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse models for breast and lung cancers, we validate the enhanced STAT3 signalling induced by the FGFR4 Arg388-variant in vivo PMID: 26675719
31. High tumor expression of FGFR4 protein is not an independent risk factor for gastric cancer initiation, but is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or in the early stages of invasion. PMID: 25684949
32. review summarizes all aspects of FGFR4 physiology and pathophysiology relevant to cacer. PMID: 23944363
33. FGFR4 is an important determinant of the aggressive phenotype of the hepatoma/hepatocarcinoma cell lines. PMID: 25031272
34. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. PMID: 25349422
35. Variants in genes involved in feedback regulation of bile acid synthesis (KLB, P=0.06 and FGFR4, P=0.09) were potentially associated with the irritable bowel syndrome-diarrhea subgroup with elevated serum C4. PMID: 25070056
36. The FGFR4 transmembrane polymorphic variants can modulate cellular growth and sensitivity to glucocorticoid hormone negative feedback. PMID: 24625004
37. High FGFR4 expression is associated with drug resistance in alveolar rhabdomyosarcoma. PMID: 24550147
38. In a Chinese population, the FGFR-4 gene polymorphism rs351855G/A was associated with an increased risk for ischemic stroke but was not associated with the ischemic stroke severity or subtype PMID: 24239227
39. FGFR4 silencing markedly reduces the migration and invasion capacity of colorectal cancer cell lines. PMID: 24410190
40. Silencing of FGFR4 reduced cell viability in a panel of colon cancer cell lines and increased caspase-dependent apoptosis. PMID: 24503538
41. The results suggest that proteins, post-translational modifications or mutations that alter structural flexibility of the TKB domain of Cbl-family proteins could regulate their binding to target phosphoproteins and thereby, affect PTK-mediated signalling. PMID: 22888118
42. expression of TGF-beta1 and FGFR4 could make synergy on the occurrence and progression of HCC, and may be used as prognosis indicators for HCC patients PMID: 24324363
43. The genotypes of G388R in FGFR4 gene were in Hardy-Weinberg equilibrium. The percentage of normal homozygotes GG was found to be (48.5%) in breast cancer, (51.8%) in lung cancer. Glycine/arginine was (36.9%) in breast cancer, (42.9%) in lung cancer. PMID: 24416997
44. The single nucleotide polymorphism rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns. PMID: 24288432
45. FGFR4 rs351855G/A polymorphism is associated with increased susceptibility to non-Hodgkin's lymphoma (NHL) and could be used as a marker for predicting the prognosis of the malignancy. PMID: 24248544
46. expression of FGFR4 in intrahepatic cholangiocarcinomas, perihilar cholangiocarcinomas and distal cholangiocarcinomas by immunohistochemistry, and association of FGFR4 with clinicopathologic parameters and survival rate PMID: 24565842
47. Inhibition of the activity of FGFR4 may be the main mechanisms of PD effect while 5-Fu reduced FGFR4 expression PMID: 24126887
48. In-depth DNA sequencing identified additional genetic coding and noncoding variants in FGFR4 that are associated with fecal bile acids excretion or colonic transit in Irritable bowel syndrome-diarrhea PMID: 24200957
49. The distribution of FGFR4 AA genotype and A-allele of rs351855G/A was significantly lower in NSCLC patients. PMID: 23524567
50. Suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for gastric cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage. PMID: 23901234

Show More

Hide All

HGNC: 3691

OMIM: 134935

KEGG: hsa:2264

STRING: 9606.ENSP00000292408

UniGene: Hs.165950